Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.

Ocumension Therapeutics

Vision Biotechnology specializes in developing and manufacturing diagnostic test kits for healthcare professionals to accurately diagnose various diseases. The company incorporates the latest advancements in biotechnology into its products, self-described as elevating healthcare through innovative testing solutions.

Metric
Company Name	Ocumension Therapeutics	Vision Biotechnology
Symbol	1.48K
MSH ID	COM:OCUMENSION	COM:VISIONBIOTECHNOLOGY
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	CN	US
Stage
Employee Count	444
Website	ocumension.com	visionbiotechnology.com
LinkedIn		visionbiotechnolgy
Founders

Metric
Market Cap	597.84M
Enterprise Value
Monthly Web Traffic		434
Web Traffic Growth		1.39
Valuation
Raised Capital

Metric
Revenue	33.89M
Revenue (LTM)
Revenue (NTM)
Gross Profit	19.86M
EBITDA	-51.59M
Operating Income	-55.31M
Net Income	-52.24M
EPS	-0.08
Diluted EPS	-0.08
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.63
Operating Profit Margin	-1.49
EBITDA Margin	-1.52
Net Profit Margin	-1.42
Return on Equity	-0.10
Return on Assets	-0.08
Return on Capital Employed	-0.10

1477

COM:OCUMENSION

Ocumension Therapeutics

Last Close

5.19

25/11 08:08

Market Cap

4.65B

Beta: -

Volume Today

1.48M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-6.82
P/B Ratio	1.00
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	24.13
EV Multiple	-9.26

Metric
Days Sales Outstanding	318.51
Days Payables Outstanding	141.35
Days Inventory Outstanding	145.42
Operating Cycle	352.44
Cash Conversion Cycle	282.03
Asset Turnover	0.08

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt	-0.85
Operating Cash Flow/Sales	-0.48
Free Cash Flow Yield	-0.17

Metric
Cash & Equivalents	144.95M
Accounts Receivable
Inventory	4.47M
Goodwill
Debt to Capitalization	0.05
Debt to Assets	0.01
Current Ratio	5.88
Quick Ratio	5.33

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	1.38
R&D to Revenue	1.16
SG&A to Revenue	1.20